Literature DB >> 8701986

CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.

H J Gruss1, A Pinto, A Gloghini, E Wehnes, B Wright, N Boiani, D Aldinucci, V Gattei, V Zagonel, C A Smith, M E Kadin, C von Schilling, R G Goodwin, F Herrmann, A Carbone.   

Abstract

The CD30 ligand (CD30L) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. Recent cloning of CD30L has enabled studies to explore its function and tissue distribution. For instance, recombinant CD30L has been shown to co-stimulate T cells and to act as mitogen for Hodgkin's disease (HD)-derived cell lines. The counter-receptor for CD30L, ie, CD30, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed-Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. In the present study, recombinant membrane-bound and soluble human CD30L were instrumental to raise a monoclonal antibody (M80) recognizing membrane-bound CD30L on transfected and native cells. With this reagent, a panel of cultured lymphoma-derived cell lines as well as primary normal, reactive, and HD-involved lymphoid tissues were examined for expression of CD30L by immunostaining and flow cytometry. In reactive lymphnodes and tonsils, CD30L was expressed by a small subset of lymphoid cells, histiocytes, and granulocytes. Higher levels of CD30L expression were noted in HD lesions among bystander cells; ie, T cells and granulocytes that surrounded H-RS cells. Native CD30L displayed at the cell surface was functionally active as shown by the ability of fixed granulocytes to interact with CD30+ cell lines. Moreover, CD30L was detectable, although to a lower staining intensity, in primary H-RS cells of all HD tissues investigated regardless of the histological subtype and the phenotype of H-RS cells (ie, CD30+/CD40+ versus CD30-/CD40+). Co-expression of CD30 and CD30L that was seen on H-RS cells of all, except the CD30- nodular lymphocyte predominant, subtypes of HD may point to the use of this pair of molecules in paracrine and/or autocrine mitogenic cell interactions. Monoclonal antibody M80 may thus represent a useful tool for studying CD30L expression on cultured cell lines and primary cells from normal, reactive, and malignant tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701986      PMCID: PMC1865328     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Comparative study of eosinophil purification on Nycodenz, Metrizamide and Percoll density gradients.

Authors:  N W Brattig; C E Medina-De la Garza; F W Tischendorf
Journal:  Eur J Haematol       Date:  1987-08       Impact factor: 2.997

2.  The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease.

Authors:  S Poppema
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

3.  Molecular pathways of adhesion in spontaneous rosetting of T-lymphocytes to the Hodgkin's cell line L428.

Authors:  M E Sanders; M W Makgoba; E H Sussman; G E Luce; J Cossman; S Shaw
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts.

Authors:  R Andreesen; J Osterholz; G W Löhr; K J Bross
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

6.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

Review 7.  CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.

Authors:  F Herrmann
Journal:  Leuk Lymphoma       Date:  1996-02

8.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

9.  Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells.

Authors:  T T Hecht; D L Longo; J Cossman; J B Bolen; S M Hsu; M Israel; R I Fisher
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

10.  Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.

Authors:  H Stein; J Gerdes; U Schwab; H Lemke; D Y Mason; A Ziegler; W Schienle; V Diehl
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

View more
  11 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Transformation of follicular lymphoma to Epstein-Barr virus-related Hodgkin-like lymphoma.

Authors:  Madhu P Menon; Lloyd Hutchinson; Joanne Garver; Elaine S Jaffe; Bruce A Woda
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

3.  Association of TNFSF8 polymorphisms with peripheral neutrophil count.

Authors:  Adelaide M Arruda-Olson; Véronique L Roger; High S Chai; Mariza de Andrade; Brooke L Fridley; Julie M Cunningham; Sherine E Gabriel; Suzette J Bielinski
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

4.  Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.

Authors:  Marie Fischer; Ilkka T Harvima; Ricardo F S Carvalho; Christine Möller; Anita Naukkarinen; Gunilla Enblad; Gunnar Nilsson
Journal:  J Clin Invest       Date:  2006-09-07       Impact factor: 14.808

5.  Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

Authors:  April Chiu; Weifeng Xu; Bing He; Stacey R Dillon; Jane A Gross; Eric Sievers; Xugang Qiao; Paul Santini; Elizabeth Hyjek; Joong-won Lee; Ethel Cesarman; Amy Chadburn; Daniel M Knowles; Andrea Cerutti
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

Review 6.  CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Authors:  Geetika Bhatt; Kami Maddocks; Beth Christian
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 7.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

Review 8.  Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Authors:  Xueyan Chen; Lorinda A Soma; Jonathan R Fromm
Journal:  Onco Targets Ther       Date:  2013-12-19       Impact factor: 4.147

9.  Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.

Authors:  Marta Bertolini; Federica Zilio; Alfredo Rossi; Patrick Kleditzsch; Vladimir E Emelianov; Amos Gilhar; Aviad Keren; Katja C Meyer; Eddy Wang; Wolfgang Funk; Kevin McElwee; Ralf Paus
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

Review 10.  Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Authors:  C A van der Weyden; S A Pileri; A L Feldman; J Whisstock; H M Prince
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.